Q-omics provides the consensus-scored RPL23P10 profile across patient tissues and cancer cell-line models. RPL23P10 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RPL23P10 is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, RPL23P10 RNA expression shows 6,365 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, THCA, and TGCT as cancer lineages where RPL23P10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL23P10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL23P10 survival associations across molecular data types. RPL23P10 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL23P10 RNA expression–survival associations across cancer types. High RPL23P10 expression shows unfavorable associations in UCEC, PAAD, THYM, KIRC and CESC, but favorable associations in HNSC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify UCEC as the clearest survival context for RPL23P10 RNA expression.
This table summarizes RPL23P10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL23P10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL23P10 shows lower tumor expression in THCA and higher tumor expression in LIHC, LUSC and STAD. The THCA box plot shows higher RPL23P10 RNA expression in normal versus tumor tissue (log2 FC = −0.054, t-test p < 0.001).
This table shows molecular features associated with RPL23P10 in patient tissues and cancer cell lines. In patient samples, RPL23P10 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
